Action Galapagos - GLPG

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

Dernier

24,68

Prix Achat

24,62

Prix Vente

24,68

Volume échangé

21 180

24,00 Fourchette du Jour 24,68

20,00 Plage de 52 semaines 31,08

Cap du marché

1,626B

Clôture Veille

23,96

Ouverture

24,06

Dernière Transaction

24.68

Dernière heure de transaction

10:05:10

Volume financier

VWAP

Volume moyen (3 m)

125 802

Actions en circulation

65 897 000

Rendement du Dividende

Ratio Cours sur Bénéfices

21,47

Bénéfice par action (BPA)

1,12

Chiffre d'affairess

410,12M

Bénéfice net

74,08M

Secteur

Coml Physical, Biologcl Resh

Industrie

Coml Physical, Biologcl Resh

Site Web

www.glpg.com

Siège social

Mechelen, Antwerp, Bel

Fondé

Galapagos est coté dans le secteur Coml Physical, Biologcl Resh de la Euronext avec le ticker GLPG. Le dernier cours de clôture d'Galapagos était de 23,96 €. Au cours de la dernière année, les actions de Galapagos ont été négociées dans une fourchette de prix de 20,00 € à 31,08 €.

Galapagos compte actuellement 65 897 000 actions en circulation. La capitalisation boursière d'Galapagos est de 1,58 € milliard. Galapagos a un ratio cours/bénéfice (ratio PE) de 21.47.

Galapagos Presented New Data at ICML 2025 From Cohort 3 of ATALANTA-1 in Relapsed/Refractory Indolent NHL Patients, Demonstrating High Complete Response and MRD Negativity Rates With CAR-T Candidate GLPG5101

Of the 34 patients enrolled in Cohort 3 of the ATALANTA-1 Phase 1/2 study, 32 received GLPG5101; 94% were...

Galapagos Presented New Data at ICML 2025 From Cohort 3 of ATALANTA-1 in Relapsed/Refractory Indolent NHL Patients, Demonstrating High Complete Response and MRD Negativity Rates With CAR-T Candidate GLPG5101

Galapagos Presented New Data at ICML 2025 From Cohort 3 of ATALANTA-1 in Relapsed/Refractory Indolent NHL Patients, Demonstrating High Complete...

Galapagos to Present New ATALANTA-1 CAR-T Data at EHA 2025, Highlighting Low Toxicity and Rapid, Decentralized Delivery of Fresh, Early-Memory-Enriched GLPG5101 in R/R NHL

Galapagos to Present New ATALANTA-1 CAR-T Data at EHA 2025, Highlighting Low Toxicity and Rapid, Decentralized Delivery of Fresh...

Galapagos to Present New ATALANTA-1 CAR-T Data at EHA 2025, Highlighting Low Toxicity and Rapid, Decentralized Delivery of Fresh, Early-Memory-Enriched GLPG5101 in R/R NHL

Data reported from the ongoing ATALANTA-1 Phase 1/2 study in a heavily pretreated relapsed refractory...

Galapagos Creates New Subscription Right Plan

Galapagos Creates New Subscription Right Plan Mechelen, Belgium; May 27, 2025, 22:30 CET; regulated information – Galapagos NV (Euronext &...

Galapagos Announces Oral Presentations at EHA and ICML 2025 Featuring Promising New Data from ATALANTA-1 study of Investigational CAR-T Candidate GLPG5101

Galapagos Announces Oral Presentations at EHA and ICML 2025 Featuring Promising New Data from ATALANTA-1 study of Investigational CAR-T Candidate...

Galapagos Announces Oral Presentations at EHA and ICML 2025 Featuring Promising New Data from ATALANTA-1 study of Investigational CAR-T Candidate GLPG5101

Mechelen, Belgium; May 14, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG), a global biotechnology...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	-0.12	-0.483870967742	24.8	25.38	23.78	99907	24.52877428	DE
4	-0.74	-2.91109362707	25.42	26.2	23.78	92436	25.08679481	DE
12	4.08	19.8058252427	20.6	26.38	20	125802	23.8334071	DE
26	-0.84	-3.29153605016	25.52	31.08	20	123249	24.23929694	DE
52	0.32	1.31362889984	24.36	31.08	20	107537	24.76309013	DE
156	-26.96	-52.2075910147	51.64	57.08	20	129815	35.31547432	DE
260	-161.12	-86.7168998924	185.8	191.75	20	239521	63.27424068	DE

GLPG - Frequently Asked Questions (FAQ)

What is the current Galapagos share price?

The current share price of Galapagos is 24,68 €

How many Galapagos shares are in issue?

Galapagos has 65 897 000 shares in issue

What is the market cap of Galapagos?

The market capitalisation of Galapagos is EUR 1,58B

What is the 1 year trading range for Galapagos share price?

Galapagos has traded in the range of 20,00 € to 31,08 € during the past year

What is the PE ratio of Galapagos?

The price to earnings ratio of Galapagos is 21,47

What is the cash to sales ratio of Galapagos?

The cash to sales ratio of Galapagos is 3,88

What is the reporting currency for Galapagos?

Galapagos reports financial results in EUR

What is the latest annual turnover for Galapagos?

The latest annual turnover of Galapagos is EUR 410,12M

What is the latest annual profit for Galapagos?

The latest annual profit of Galapagos is EUR 74,08M

What is the registered address of Galapagos?

The registered address for Galapagos is GENERAAL DE WITTELAAN L11, MECHELEN, ANTWERP, A3 2800

What is the Galapagos website address?

The website address for Galapagos is www.glpg.com

Which industry sector does Galapagos operate in?

Galapagos operates in the COML PHYSICAL, BIOLOGCL RESH sector

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
ORDDSOrdissimo	0,007 € (59,09%)	27,84k
ALALOAcheterLouerFR	0,001 € (25,00%)	62,32M
FPGUnion Tech Info	0,188 € (20,51%)	267,92k
BIOSBiosenic	0,0025 € (19,05%)	5,48M
ALMEXMexedia SPA	7,55 € (18,90%)	1,08k
VALDSValbiotis SA	0,0001 € (-75,00%)	37,79k
BNBSTonner Drones	0,0065 € (-18,75%)	422k
ALESAEcoslops	0,902 € (-13,27%)	5,86k
ALBDMBD Multi-Media	12,40 € (-10,47%)	52,19k
ALBLUBluelinea SA	0,54 € (-9,24%)	907
ALALOAcheterLouerFR	0,001 € (25,00%)	62,32M
ALHPIHopium SA	0,0003 € (0,00%)	47,81M
ALNEVNeovacs	0,0022 € (-8,33%)	11,94M
BCPBanco Comercial Portugues SA	0,6534 € (2,29%)	8,61M
ALEUPEuroplasma	0,007 € (-5,41%)	6,85M

Forums

Afficher les forums

Galapagos - GLPG (Euronext Belgique)

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Galapagos (GLPG)

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

À propos de Galapagos

GLPG Dernières nouvelles

Galapagos Presented New Data at ICML 2025 From Cohort 3 of ATALANTA-1 in Relapsed/Refractory Indolent NHL Patients, Demonstrating High Complete Response and MRD Negativity Rates With CAR-T Candidate GLPG5101

Galapagos Presented New Data at ICML 2025 From Cohort 3 of ATALANTA-1 in Relapsed/Refractory Indolent NHL Patients, Demonstrating High Complete Response and MRD Negativity Rates With CAR-T Candidate GLPG5101

Galapagos to Present New ATALANTA-1 CAR-T Data at EHA 2025, Highlighting Low Toxicity and Rapid, Decentralized Delivery of Fresh, Early-Memory-Enriched GLPG5101 in R/R NHL

Galapagos to Present New ATALANTA-1 CAR-T Data at EHA 2025, Highlighting Low Toxicity and Rapid, Decentralized Delivery of Fresh, Early-Memory-Enriched GLPG5101 in R/R NHL

Galapagos Creates New Subscription Right Plan

Galapagos Announces Oral Presentations at EHA and ICML 2025 Featuring Promising New Data from ATALANTA-1 study of Investigational CAR-T Candidate GLPG5101

Galapagos Announces Oral Presentations at EHA and ICML 2025 Featuring Promising New Data from ATALANTA-1 study of Investigational CAR-T Candidate GLPG5101

Galapagos Announces Strategic Update on Proposed Separation, Executive Leadership Transition and Board Changes

Galapagos Announces Strategic Update on Proposed Separation, Executive Leadership Transition and Board Changes

Galapagos Reports First Quarter 2025 Financial Results, Recent Business Highlights and Near-Term Catalysts

Galapagos Presented New Data at ICML 2025 From Cohort 3 of ATALANTA-1 in Relapsed/Refractory Indolent NHL Patients, Demonstrating High Complete Response and MRD Negativity Rates With CAR-T Candidate GLPG5101

Galapagos Presented New Data at ICML 2025 From Cohort 3 of ATALANTA-1 in Relapsed/Refractory Indolent NHL Patients, Demonstrating High Complete Response and MRD Negativity Rates With CAR-T Candidate GLPG5101

Galapagos to Present New ATALANTA-1 CAR-T Data at EHA 2025, Highlighting Low Toxicity and Rapid, Decentralized Delivery of Fresh, Early-Memory-Enriched GLPG5101 in R/R NHL

Galapagos to Present New ATALANTA-1 CAR-T Data at EHA 2025, Highlighting Low Toxicity and Rapid, Decentralized Delivery of Fresh, Early-Memory-Enriched GLPG5101 in R/R NHL

Galapagos Creates New Subscription Right Plan

Galapagos Announces Oral Presentations at EHA and ICML 2025 Featuring Promising New Data from ATALANTA-1 study of Investigational CAR-T Candidate GLPG5101

Galapagos Announces Oral Presentations at EHA and ICML 2025 Featuring Promising New Data from ATALANTA-1 study of Investigational CAR-T Candidate GLPG5101

Galapagos Announces Strategic Update on Proposed Separation, Executive Leadership Transition and Board Changes

GLPG - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Galapagos (GLPG) Cours

Galapagos (GLPG)

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

À propos de Galapagos

GLPG Dernières nouvelles

Galapagos Presented New Data at ICML 2025 From Cohort 3 of ATALANTA-1 in Relapsed/Refractory Indolent NHL Patients, Demonstrating High Complete Response and MRD Negativity Rates With CAR-T Candidate GLPG5101

Galapagos Presented New Data at ICML 2025 From Cohort 3 of ATALANTA-1 in Relapsed/Refractory Indolent NHL Patients, Demonstrating High Complete Response and MRD Negativity Rates With CAR-T Candidate GLPG5101

Galapagos to Present New ATALANTA-1 CAR-T Data at EHA 2025, Highlighting Low Toxicity and Rapid, Decentralized Delivery of Fresh, Early-Memory-Enriched GLPG5101 in R/R NHL

Galapagos to Present New ATALANTA-1 CAR-T Data at EHA 2025, Highlighting Low Toxicity and Rapid, Decentralized Delivery of Fresh, Early-Memory-Enriched GLPG5101 in R/R NHL

Galapagos Creates New Subscription Right Plan

Galapagos Announces Oral Presentations at EHA and ICML 2025 Featuring Promising New Data from ATALANTA-1 study of Investigational CAR-T Candidate GLPG5101

Galapagos Announces Oral Presentations at EHA and ICML 2025 Featuring Promising New Data from ATALANTA-1 study of Investigational CAR-T Candidate GLPG5101

Galapagos Announces Strategic Update on Proposed Separation, Executive Leadership Transition and Board Changes

Galapagos Announces Strategic Update on Proposed Separation, Executive Leadership Transition and Board Changes

Galapagos Reports First Quarter 2025 Financial Results, Recent Business Highlights and Near-Term Catalysts

Galapagos Presented New Data at ICML 2025 From Cohort 3 of ATALANTA-1 in Relapsed/Refractory Indolent NHL Patients, Demonstrating High Complete Response and MRD Negativity Rates With CAR-T Candidate GLPG5101

Galapagos Presented New Data at ICML 2025 From Cohort 3 of ATALANTA-1 in Relapsed/Refractory Indolent NHL Patients, Demonstrating High Complete Response and MRD Negativity Rates With CAR-T Candidate GLPG5101

Galapagos to Present New ATALANTA-1 CAR-T Data at EHA 2025, Highlighting Low Toxicity and Rapid, Decentralized Delivery of Fresh, Early-Memory-Enriched GLPG5101 in R/R NHL

Galapagos to Present New ATALANTA-1 CAR-T Data at EHA 2025, Highlighting Low Toxicity and Rapid, Decentralized Delivery of Fresh, Early-Memory-Enriched GLPG5101 in R/R NHL

Galapagos Creates New Subscription Right Plan

Galapagos Announces Oral Presentations at EHA and ICML 2025 Featuring Promising New Data from ATALANTA-1 study of Investigational CAR-T Candidate GLPG5101

Galapagos Announces Oral Presentations at EHA and ICML 2025 Featuring Promising New Data from ATALANTA-1 study of Investigational CAR-T Candidate GLPG5101

Galapagos Announces Strategic Update on Proposed Separation, Executive Leadership Transition and Board Changes

GLPG - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Connectez-vous

Supprimer les publicités